Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 8Phase 1/2 4Phase NA 3Phase EARLY_PHASE1 3Phase 3 3Phase 4 2

Status

Unknown 3Terminated 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 538Neoplasms 393Prostatic Neoplasms 261Colorectal Neoplasms 252Lung Neoplasms 202Carcinoma, Hepatocellular 177Stomach Neoplasms 162Pancreatic Neoplasms 151Rectal Neoplasms 143Motor Activity 128Colonic Neoplasms 126Carcinoma, Non-Small-Cell Lung 118Uterine Cervical Neoplasms 113Polycystic Ovary Syndrome 96Head and Neck Neoplasms 96Esophageal Neoplasms 92Neoplasm Metastasis 71Brain Neoplasms 68Liver Neoplasms 67Ovarian Neoplasms 65Recurrence 60Urinary Bladder Neoplasms 59Pain 55Fatigue 54Lymphoma 53Endometrial Neoplasms 52Anxiety Disorders 50Melanoma 48Thyroid Neoplasms 47Pain, Postoperative 41

Interventions

spartalizumab 1Rituximab 1Gemcitabine 1Dexamethasone 1Clinical Protocols 1Cisplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Unknown × Lymphoma, T-Cell × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

NCT05772728 2023-03-16

Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)

The First Affiliated Hospital with Nanjing Medical University

Phase NA Unknown
23 enrolled
Lymphoid

Lymphoma, T-Cell

NCT04928105 2022-05-31

Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡